Here are the 10-Q quarterly reports from Avalon GloboCare Corp. (ALBT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALBT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALBT filings page.
Avalon GloboCare reported a Q1 2026 net loss of $4.5M, wider than $2.5M a year earlier, as it invested in AI-driven software while recording no income from its former lab services equity method investment.
The company had cash of $776K at March 31, 2026 and used $2.9M in operating cash flow, contributing to a working capital deficit of about $2.8M. Management disclosed “substantial doubt” about its ability to continue as a going concern without new capital and higher revenue.
To fund operations, Avalon raised gross proceeds of $3.25M in a February 2026 private placement of common stock, pre-funded warrants and additional warrants, and added new short-term debt totaling over $1.2M. It also sold its Avalon RT 9 real estate subsidiary to its chairman for $9.0M, treating those activities as discontinued operations while shifting focus to AI and KetoAir-related businesses.
Avalon GloboCare Corp. (ALBT) reported continued operating losses and significant balance sheet activity in the six months ended June 30, 2025. The company recorded recurring net losses of approximately $15.94 million for the six-month period and generated negative operating cash flow of about $3.03 million. During Q1 2025 Avalon completed the redemption of its 40% equity interest in Lab Services MSO for aggregate cash of $1.745 million and the surrender of Series B preferred stock (carrying value $11.0 million), recognizing an increase to additional paid-in capital of $2.3487 million. The company recorded a $9.0766 million loss on extinguishment of debt related to modification/waiver of the June 2024 convertible note financing. Derivative liabilities declined, producing a fair value gain of $446,816 for the six months. The company wrote off and reserved for credit losses ($1.65 million) and reported material warrant and convertible instruments, including the June 2024 convertible note (principal $2.845 million). Avalon’s laboratory services segment ceased upon the Lab Services MSO redemption; the real property segment remains operational.